Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects

Area of Science:

• Biotechnology and Biomedical Engineering
• Cancer Therapeutics
• Molecular Medicine

Background:

• RNA interference (RNAi) using small interfering RNA (siRNA) shows therapeutic promise for cancer.
• Effective systemic delivery of siRNA to tumors remains a significant challenge for clinical translation.
• Current limitations include siRNA degradation, poor tumor biodistribution, inefficient cellular uptake, and endosomal entrapment.

Purpose of the Study:

• To review pharmacokinetic and biodistribution challenges in systemic siRNA delivery for cancer.
• To summarize current delivery systems, including liposomes, polymers, and peptides, for siRNA therapeutics.
• To discuss future perspectives and promising delivery agents evaluated in preclinical and clinical studies.

Main Methods:

• Comprehensive literature review of pharmacokinetic and biodistribution studies for systemic siRNA delivery.
• Analysis of various delivery platforms (liposomes, polymers, peptides) for cancer treatment.
• Evaluation of preclinical and clinical trial data for efficacy and safety of siRNA delivery agents.

Main Results:

• Significant challenges exist in achieving efficient and targeted delivery of siRNA to tumors.
• Liposome-, polymer-, and peptide-based systems have demonstrated potential in preclinical models for gene silencing and tumor growth inhibition.
• Certain delivery agents have shown promising efficacy in both rodent models and human clinical trials.

Conclusions:

• Overcoming delivery barriers is essential for realizing the full therapeutic potential of siRNA in oncology.
• Advanced delivery systems are crucial for improving siRNA stability, tumor targeting, and therapeutic outcomes.
• Continued research into novel delivery agents holds promise for effective siRNA-based cancer therapies.